SecBot SecBot
8-K ·Filed Apr 16, 2026

CDNA

CareDx, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001104659-26-043970
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The divestiture allows CareDx to focus on its core testing services business while receiving $170 million in cash. The strong 48% year-over-year growth in testing services revenue suggests the core business is performing well. The distribution agreement with Eurobio provides ongoing revenue from the divested products.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.42
T+0 close · Apr 16, 2026 · via day close
Latest settled
+28.28%
T+60 · $28.76
Vs SPY
+21.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $22.42entry
  2. T+1 · 7mo ago −4.46%α −5.67% · $21.42
  3. T+5 · 7mo ago −10.53%α −11.51% · $20.06
  4. T+20 · 6mo ago −8.07%α −13.89% · $20.61
  5. T+60 · 4mo ago +28.28%α +21.23% · $28.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CareDx is divesting its lab products business to Eurobio Scientific for $170 million in cash to focus on core testing services, while reporting preliminary Q1 2026 revenue of $118 million with 48% year-over-year growth in testing services revenue. The transaction includes a 6-month transition services agreement and a distribution agreement for North America.

Key Financial Metrics

EPS
$0.12
est $0.13 · -8.9%
Revenue
$118.0M
est $102.5M · +15.1% · +39.0% YoY
Rating
beat
Deal Value
$170.0M
Deal Type
sale

Key Facts

  • Divesting lab products business to Eurobio Scientific for $170 million in cash
  • Preliminary Q1 2026 revenue of $118 million, up 39% year-over-year
  • Testing services revenue of $91 million, up 48% year-over-year
  • Testing volume of 54,900, up 17% year-over-year
  • Transition services agreement for at least 6 months at Eurobio's expense
  • Eurobio grants CareDx exclusive distribution rights for post-transplant monitoring tests in North America

Financial Impact

$170 million cash proceeds from divestiture, $118 million in Q1 revenue

revenuedilutiondebt

Risk Factors

  • Execution risk in transitioning the divested business
  • Potential disruption to operations during the 6-month transition period
  • Dependence on Eurobio for future supply of divested products

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-043970
Document: tm2611749d1_8k.htm0001104659-26-043970
Document: tm2611749d1_ex99-1.htm0001104659-26-043970
Document: 0001104659-26-043970-index-headers.html0001104659-26-043970
Document: 0001104659-26-043970-index.html0001104659-26-043970
Document: 0001104659-26-043970.txt0001104659-26-043970
8-K Data (Synthetic)0001104659-26-043970

US Market Status

Market Closed · Opens Wed (9h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026